DCPH insider filings

Deciphera Pharmaceuticals, Inc. — 50 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2024-04-24. Screen DCPH transaction legs live →

Insider transaction summary — last 90 days

No insider filings (Forms 3/4/5) for DCPH between 2026-08-23 and 2026-11-21. The table below lists the most recent filings on record.

Recent insider filings — Deciphera Pharmaceuticals, Inc.

FiledFormInsiderReported transactionsSource
2024-04-244Brightstar Associates LLC — 10% ownerOption exercise/expiry (X): 48,136 @ $0.01 · Option exercise/expiry (X): 48,136 (derivative) @ $0EDGAR
2024-02-204Dhanak Dashyant — EVP & Chief Scientific OfficerGrant/award (A): 17,275 @ $0 · Grant/award (A): 69,100 (derivative) @ $0EDGAR
2024-02-204Martin Daniel C. — Chief Commercial OfficerGrant/award (A): 9,725 @ $0 · Sale (S): 2,267 @ $15.62 · Grant/award (A): 38,900 (derivative) @ $0EDGAR
2024-02-204Pitman Jama — SVP, Chief Development OfficerGrant/award (A): 9,725 @ $0 · Grant/award (A): 10,000 @ $0 · Sale (S): 2,267 @ $15.62 · Grant/award (A): 38,900 (derivative) @ $0EDGAR
2024-02-204Hoerter Steven L. — President and CEO, DirectorGrant/award (A): 298,100 (derivative) @ $0EDGAR
2024-02-204Kelly Thomas Patrick — Chief Financial OfficerGrant/award (A): 17,275 @ $0 · Sale (S): 3,010 @ $15.62 · Grant/award (A): 69,100 (derivative) @ $0EDGAR
2024-02-204Sherman Matthew L — EVP & Chief Medical OfficerGrant/award (A): 17,275 @ $0 · Sale (S): 2,615 @ $15.62 · Grant/award (A): 69,100 (derivative) @ $0EDGAR
2024-02-094Brightstar Associates LLC — 10% ownerOption exercise/expiry (X): 914,001 @ $0.01 · Option exercise/expiry (X): 914,001 (derivative) @ $0EDGAR
2024-01-184Walsh Dennis Leo — DirectorGrant/award (A): 4,727 (derivative) @ $10.58EDGAR
2024-01-184Pitman Jama — SVP, Chief Development OfficerSale (S): 1,624 @ $14.47EDGAR
2024-01-184Friedman Franklin Stuart — DirectorGrant/award (A): 4,727 (derivative) @ $10.58EDGAR
2024-01-184Martin Daniel C. — Chief Commercial OfficerSale (S): 1,624 @ $14.47EDGAR
2024-01-184Squarer Ron — DirectorGrant/award (A): 4,727 (derivative) @ $10.58EDGAR
2024-01-184Kelly Thomas Patrick — Chief Financial OfficerSale (S): 2,435 @ $14.47EDGAR
2024-01-184Allen Patricia L — DirectorGrant/award (A): 4,727 (derivative) @ $10.58EDGAR
2024-01-184Sherman Matthew L — EVP & Chief Medical OfficerSale (S): 2,435 @ $14.47EDGAR
2023-12-144Pitman Jama — See RemarksGrant/award (A): 5,576 · Sale (S): 1,662 @ $15.37EDGAR
2023-12-144Martin Daniel C. — Chief Commercial OfficerGrant/award (A): 5,576 · Sale (S): 1,727 @ $15.37EDGAR
2023-12-144Hoerter Steven L. — President and CEO, DirectorGrant/award (A): 62,500 · Sale (S): 30,664 @ $15.37EDGAR
2023-12-144Kelly Thomas Patrick — Chief Financial OfficerGrant/award (A): 8,244 · Sale (S): 2,792 @ $15.37EDGAR
2023-12-144Sherman Matthew L — EVP & Chief Medical OfficerGrant/award (A): 8,244 · Sale (S): 2,792 @ $15.37EDGAR
2023-12-014Martin Daniel C. — Chief Commercial OfficerSale (S): 17,801 @ $12.57EDGAR
2023-10-314Pitman Jama — See RemarksGrant/award (A): 5,576 · Sale (S): 1,407 @ $12.02EDGAR
2023-10-314Martin Daniel C. — Chief Commercial OfficerGrant/award (A): 5,576 · Sale (S): 1,407 @ $12.02EDGAR
2023-10-314Hoerter Steven L. — President and CEO, DirectorGrant/award (A): 62,500 · Sale (S): 21,573 @ $12.02EDGAR
2023-10-314Kelly Thomas Patrick — Chief Financial OfficerGrant/award (A): 8,244 · Sale (S): 2,316 @ $12.02EDGAR
2023-10-314Sherman Matthew L — EVP & Chief Medical OfficerGrant/award (A): 8,244 · Sale (S): 2,360 @ $12.02EDGAR
2023-10-044Sherman Matthew L — EVP & Chief Medical OfficerSale (S): 2,942 @ $12.68EDGAR
2023-09-194Dhanak Dashyant — EVP & Chief Scientific OfficerGrant/award (A): 65,900 @ $0 · Grant/award (A): 75,000 @ $0 · Grant/award (A): 65,900 (derivative) @ $0EDGAR
2023-06-234Bristol James Arthur — DirectorGrant/award (A): 30,000 (derivative) @ $0EDGAR
2023-06-234Walsh Dennis Leo — DirectorGrant/award (A): 30,000 (derivative) @ $0EDGAR
2023-06-234Martin John Richard — DirectorGrant/award (A): 30,000 (derivative) @ $0EDGAR
2023-06-234Benz Edward J. JR — DirectorGrant/award (A): 30,000 (derivative) @ $0EDGAR
2023-06-234Friedman Franklin Stuart — DirectorGrant/award (A): 30,000 (derivative) @ $0EDGAR
2023-06-234Kelley Susan L. — DirectorGrant/award (A): 30,000 (derivative) @ $0EDGAR
2023-06-234Squarer Ron — DirectorGrant/award (A): 30,000 (derivative) @ $0EDGAR
2023-06-234Allen Patricia L — DirectorGrant/award (A): 30,000 (derivative) @ $0EDGAR
2023-06-214Pitman Jama — See RemarksSale (S): 1,238 @ $14.40EDGAR
2023-06-214Martin Daniel C. — Chief Commercial OfficerSale (S): 1,238 @ $14.40EDGAR
2023-06-214Flynn Daniel Lee — Chief Scientific OfficerSale (S): 1,655 @ $14.40EDGAR
2023-06-214Kelly Thomas Patrick — Chief Financial OfficerSale (S): 1,655 @ $14.40EDGAR
2023-06-214Sherman Matthew L — EVP & Chief Medical OfficerSale (S): 1,655 @ $14.40EDGAR
2023-06-124Friedman Franklin Stuart — DirectorPurchase (P): 10,000 @ $13.88EDGAR
2023-05-124Walsh Dennis Leo — DirectorPurchase (P): 11,000 @ $13.86EDGAR
2023-03-234Hoerter Steven L. — President and CEO, DirectorSale (S): 7,500 @ $15.57EDGAR
2023-03-014Brightstar Associates LLC — 10% ownerOption exercise/expiry (X): 2,427,693 @ $0.01 · Option exercise/expiry (X): 2,427,693 (derivative) @ $0EDGAR
2023-02-174Martin Daniel C. — Chief Commercial OfficerGrant/award (A): 11,151 @ $0 · Sale (S): 1,159 @ $15.10 · Grant/award (A): 44,600 (derivative) @ $0EDGAR
2023-02-174Flynn Daniel Lee — Chief Scientific OfficerGrant/award (A): 16,488 @ $0 · Sale (S): 1,370 @ $15.10 · Grant/award (A): 65,900 (derivative) @ $0EDGAR
2023-02-174Kelly Thomas Patrick — Chief Financial OfficerGrant/award (A): 16,488 @ $0 · Sale (S): 1,370 @ $15.10 · Grant/award (A): 65,900 (derivative) @ $0EDGAR
2023-02-174Sherman Matthew L — EVP & Chief Medical OfficerGrant/award (A): 16,488 @ $0 · Sale (S): 971 @ $15.10 · Grant/award (A): 65,900 (derivative) @ $0EDGAR

Recent 8-K events — Deciphera Pharmaceuticals, Inc.

Items classified from EDGAR index headers. Browse recent 8-K filings market-wide, by item code →

FiledFormItems reportedSource
2024-06-118-K1.02 — Termination of a Material Definitive Agreement
2.01 — Completion of Acquisition or Disposition of Assets
3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
3.03 — Material Modification to Rights of Security Holders
5.01 — Changes in Control of Registrant
5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
8.01 — Other Events
9.01 — Financial Statements and Exhibits
EDGAR
2024-04-298-K1.01 — Entry into a Material Definitive Agreement
8.01 — Other Events
9.01 — Financial Statements and Exhibits
EDGAR
2024-02-068-K2.02 — Results of Operations and Financial Condition
9.01 — Financial Statements and Exhibits
EDGAR
2024-01-088-K2.02 — Results of Operations and Financial Condition
8.01 — Other Events
9.01 — Financial Statements and Exhibits
EDGAR
2023-10-308-K2.02 — Results of Operations and Financial Condition
8.01 — Other Events
9.01 — Financial Statements and Exhibits
EDGAR
2023-08-098-K2.02 — Results of Operations and Financial Condition
9.01 — Financial Statements and Exhibits
EDGAR
2023-08-038-K5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
9.01 — Financial Statements and Exhibits
EDGAR
2023-06-228-K5.07 — Submission of Matters to a Vote of Security HoldersEDGAR
2023-05-038-K2.02 — Results of Operations and Financial Condition
9.01 — Financial Statements and Exhibits
EDGAR
2023-02-078-K2.02 — Results of Operations and Financial Condition
9.01 — Financial Statements and Exhibits
EDGAR
Need this as JSON? GET https://api.filingpulse.io/v1/insider-trades?ticker=DCPH returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. Get a free API key → · API docs